(Q35999552)

English

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Ebrahim S Delpassand

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Amin Samarghandi

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jennifer Sims Mourtada

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sara Zamanian

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Gregory D Espenan

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Roozbeh Sharif

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Shawn Mackenzie

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Kambiz Kosari

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Omar Barakat

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Shagufta Naqvi

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

John E Seng

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Lowell Anthony

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

11 May 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

472-480

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

2 October 2017

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Epidemiology of neuroendocrine tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364554

23 September 2018

High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin receptor: scintigraphy and radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history

1 reference

https://pubmed.ncbi.nlm.nih.gov/22737186

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.7150/THNO.3739

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35999552&oldid=1610873645"